

Our ref: IG/FOI/FOI.187.25

20 February 2025

Sent via email to: [REDACTED]

Dear [REDACTED],

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 30 January 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require.

For ease of reference your request is set out below and my response follows each question individually.

Your Freedom of Information (FOI) Request and PTHB response (Bold):

Please could you confirm whether Powys Teaching Health Board has any local treatment guidelines for the treatment of the following conditions. If a guideline exists, please could a copy or an externally accessible URL be supplied.

Previous FOI's may have been submitted relating to these conditions we are therefore asking if new guidelines have been published since the initial response.

Disease/ Condition	Is a local treatment guideline available? (If Yes please can a copy be supplied)
Heart failure	No - PTHB / CCS 1 Community Cardiology service Standard Operating Procedure is currently being updated.
Axial spondyloarthritis (axSpA)/ Ankylosing spondylitis (AS)	No
Rheumatoid Arthritis	No
Crohn's Disease	No
Diabetes	Yes <u>All Wales advice on sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 2 diabetes and cardiovascular disease - All Wales Therapeutics and Toxicology Centre</u>

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

	All Wales SM Blood Glucose 2024 guidance v0.2.docx
Psoriasis	No
Psoriatic Arthritis(PsA)	No
Hidradenitis Suppurativa	No
Atopic Dermatitis/Eczema	No
Chronic obstructive pulmonary disease (COPD)	Yes https://awttc.nhs.wales/files/guidelines-and-pils/all-wales-copd-management-and-prescribing-guideline-pdf/
Growth Hormone Deficiency	No
Ulcerative Colitis	No

The following guidelines have previously been supplied to us by FOI, please could you confirm if these documents are still active or if they have been updated since the previous response. Where possible previous FOI details have been supplied.

Therapy	Osteoporosis	Anti-Obesity
Title	Administration of Denosumab (Prolia®) for the Prevention of Osteoporotic Fractures.	Accessing Adult Weight Management Services in Powys
Title	01/04/15	27/06/24
Has this document been updated since the FOI response? (If Yes please can an updated copy be supplied)	No	National guidelines relating to weight management: all-wales-weight-management-pathway-2021.pdf Weight Management Medication Pathway: Addendum for the All Wales Weight Management Pathway
Is this document still valid?	No	Yes

Please be advised that details of all of our Medicines Management Policies can be accessed from the Medicines Management pages of the health board's website: [Information for Health Care Professionals - Powys Teaching Health Board](#)

Links to local and national guidelines relating to medicines can also be found in the health board's formulary: [Formulary](#)

Wherever possible across Wales, we take a once for Wales approach. The 'All Wales' guidelines can be located on the AWTTTC website: [Home - All Wales Therapeutics and Toxicology Centre](#)

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you

would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via Powys.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Kate Wright
Executive Medical Director



David Farnsworth
Assistant Director, Community Services Group

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.